Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients
Clinical and Translational Oncology, 06/12/2012
Sanchez–Rovira P et al. – The results show an effective regimen with acceptable tolerability. The data suggest that not only classical markers, but also survivin and pERK could be involved in the response to GAT, which may contribute to therapy individualisation in future study designs.